J
Johannes Nippgen
Researcher at Merck KGaA
Publications - 21
Citations - 4669
Johannes Nippgen is an academic researcher from Merck KGaA. The author has contributed to research in topics: Cetuximab & Irinotecan. The author has an hindex of 9, co-authored 19 publications receiving 4377 citations. Previous affiliations of Johannes Nippgen include Merck & Co..
Papers
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon,Karen Fink,Tom Mikkelsen,Timothy F. Cloughesy,Alison M. O'Neill,Scott R. Plotkin,Michael Glantz,Paula Ravin,Jeffrey J. Raizer,Keith M. Rich,David Schiff,William R. Shapiro,Susan Burdette-Radoux,Edward J. Dropcho,Sabine M. Wittemer,Johannes Nippgen,Martin Picard,L. Burt Nabors +17 more
TL;DR: Cilengitide monotherapy is well tolerated and exhibits modest antitumor activity among recurrent GBM patients, and additional studies integrating cilENGitide into combinatorial regimens for GBM are warranted.
Journal ArticleDOI
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
E. Van Cutsem,M. Nowacki,István Láng,Stefano Cascinu,I. Shchepotin,Juan Maurel,Ph. Rougier,David Cunningham,Johannes Nippgen,C.-H. Köhne +9 more
TL;DR: The present trial investigated the effectiveness of cetuximab in combination with standard F OLFIRI compared with FOLFIRI alone in the first-line treatment of pts with epidermal growth factor receptor (EGFR)-expressing mCRC.
Journal ArticleDOI
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Helmut Friess,Jan M. Langrehr,Helmut Oettle,Jochen Raedle,Marco Niedergethmann,Christian Dittrich,Dieter K Hossfeld,Herbert Stöger,Bart Neyns,Peter Herzog,Pascal Piedbois,Frank Dobrowolski,Werner Scheithauer,Robert E. Hawkins,Frieder Katz,Peter Balcke,Jan B. Vermorken,Simon van Belle,Neville Davidson,Albert Abad Esteve,Daniel Castellano,Jörg Kleeff,Adrien A. Tempia-Caliera,Andreas Kovar,Johannes Nippgen +24 more
TL;DR: The combination regimen was well tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent and the observations lay in the range of other clinical studies in this setting.
Journal ArticleDOI
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
S. Tejpar,Marc Peeters,Yves Humblet,Jan B. Vermorken,G. De Hertogh,W. De Roock,Johannes Nippgen,A. von Heydebreck,C. Stroh,E. Van Cutsem +9 more
TL;DR: This work has shown that in pts with mCRC after failure of irinotecan-based therapy, the efficacy could be improved by escalating the dose of cetuximab, and this work aims to demonstrate this in patients with a prior history of central giant cell granuloma.